Some existing anti-cancer drugs may act in part by targeting RNA, study shows JUPITER, FL June 28, 2018 Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti-cancer drugs may work, in part, by binding tightly to RNA, the regulators of the basic activities of life within cells. The research offers another approach for tackling diseases that have been considered undruggable, including amyotrophic lateral sclerosis (ALS), muscular dystrophy, cystic fibrosis and certain cancers.
Known drugs made in the era when RNAs were not considered drug targets are, in fact, binding RNA, and causing some of the drug's effects by modulating targets that were not previously considered, says chemist Matthew D. Disney, PhD, professor on the Florida campus of Scripps Research, who led the study. We found broad drug classes that bind RNA. There is reason to believe that not only could known drugs bind RNA in a disease setting, but there is more evidence that one should consider RNA as a target in drug-discovery efforts.
While the universe of human proteins consists of about 20,000 varieties, the universe of human RNAs is closer to 200,000, potentially offering other effective opportunities to intervene, Disney says.
The paper, Approved Anti-Cancer Drugs Target Oncogenic Non-Coding RNAs, appears in the journal Cell Chemical Biology June 28.
Most drugs on the market today come in the form of pills that contain active small molecule medicines. Through a process called structure-based drug design, chemists optimize such small molecule drugs to bind selectively and tightly to their biologic targets. The target is generally the pocket of a protein important in disease progression.
But there are limitations to small molecules. Because proteins are large and contain many folds and crevasses, sometimes key disease-driving areas are inaccessible to small molecule drugs. This problem has inspired Disney and other researchers to take a closer look at the roots of diseases. Because RNAs are involved in assembling proteins within cells, some have hypothesized that undruggable diseases could be modified prior to protein fabrication, at the RNA level.
Disney says he has encountered skepticism about the value of pursuing RNA-binding small molecule therapeutics. The thought was RNAs presented too challenging a target due to their size, movement, changeability and uncertain specificity. RNAs are shape-shifters, and generally thought to lack clearly defined structures to which a small molecule drug could obviously bind. Yet all along, as the new study shows, existing drugs have been doing just that and binding defined pockets in an RNA Disney says.
To explore his hypothesis, Disney devised a system for rapidly testing a large library of existing drugs against a wide variety of RNA molecules. He calls his testing system AbsorbArray.
Basically, we figured out a way in which we could test millions of combinations of small molecule medicines and RNA folds that bind to each other, Disney says.
With AbsorbArray, the researchers identified the three drugs that bound to one type of microRNA and found they were microRNAs involved in every cancer. The drugs, called kinase- and topoisomerase-inhibitors, interfere with expression of a microRNA called miR-21. In further testing, it became clear that interfering with that microRNA prevented cancer cells from invading tissue.
This data supports the hypothesis that very average-looking small molecule drugs can target RNA, Disney says.
Conducting the experiment required using a library of known small molecule drugs, and testing them against another library, of pre-messenger RNA, a process Disney called two-dimensional combinatorial screening. He was assisted in that effort by Arnab K. Chatterjee, PhD, at the California Institute for Biomedical Research (Calibr), a division of Scripps Research, which supplied the RNA splicing modulator library for the experiments.
What is particularly interesting to me as a chemist is how existing compounds that have been tested in the clinic and optimized on one protein target may have additional novel activities in targeting RNA as well, Chatterjee says.
Looking forward, the next question is whether the selectivity and drug-like properties of these anti-cancer compounds will extend to diseases other than cancers, Chatterjee says.
In recent years, the Disney lab has found RNA-binding molecules applicable to many diseases, including ALS, myotonic dystrophy type 2, triple-negative breast cancer, inflammation, cystic fibrosis, Alport syndrome and more. The AbsorbArray findings underscore the likely value of continuing to move these disease-relevant RNA-binding compounds toward a clinical setting, Disney said.
Drugs that patients take every day apparently target RNA, which is only recently being thought of as a target for small molecule medicines, Disney says. As new RNAs are found to cause disease, routine medicines may be identified to target them. This would change the perception of RNAs as an afterthought in drug discovery and bring them to the forefront.
Other authors of the study, Approved Anti-Cancer Drugs Target Oncogenic Non-Coding RNAs, include Sai Pradeep Velagapudi, Matthew G. Costales, Balayeshwanth R. Vummidi, Yoshio Nakai, Alicia J. Angelbello, Tuan Tran, Hafeez S. Haniff, Yasumasa Matsumoto, Zi Fu Wang and Jessica L. Childs-Disney of Scripps Research and Arnab K. Chatterjee of the California Institute for Biomedical Research (CALIBR).
This work was supported by the Scheller Graduate Student Fellowship, a Swiss National Science Foundation Early Postdoc Mobility Fellowship, and the National Institutes of Health (grant 5R01GM097455).
About Scripps Research
Scripps Research is one of the world
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
07/10/2026
Dalet, a leading technology and service provider for media-rich organizations, today announced the latest Long-Term Supported (LTS) release of Dalet Flex. Build...
06/09/2026
June 9 2026, 23:00 (PDT) Dolby and MagentaTV Bring Fans Closer to the FIFA Worl...
19/08/2026
As the cost of IP nears price parity with traditional SDI, Reynolds argues that ...
19/08/2026
A private 5G bubble was chosen instead of traditional broadcast RF for the race ...
19/08/2026
(L-R) Rafael Manuel and Isabel Sicat attend the Filipi ana premiere during the 2026 Sundance Film Festival at The Ray Theatre on January 23, 2026, in Park Cit...
19/08/2026
Studio owners invited to have their say on rates cuts
The Music Producers Guild (MPG) are inviting UK-based studios to take part in an in-depth survey that ...
19/08/2026
Vintage-inspired desktop interface revealed
Harrison's latest hardware offering sees them head into the world of audio interfaces, delivering a 10-in/12...
19/08/2026
Granular effect remains locked to scale and tempo
Described as your dream granular effect , Minimal Audio's latest creation is capable of turning any s...
19/08/2026
First polyphonic SWAM instrument incoming
Audio Modeling's latest physical-modelling orchestral instrument is just around the corner, and is now availab...
19/08/2026
World Cup Games Generate 84 Billion Minutes Across FOX, Fox Sports 1 and NBCU...
19/08/2026
July brought typical peak-holiday drops in viewership, driven primarily by viewers stepping away from screens and a visible decline in reach across both traditi...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Henry joins BCE as the company accelerates its commercial strategy and expands its international presence across the media, broadcast and technology markets. He...
19/08/2026
iWedia, a leading provider of software solutions for connected TV devices, today announced a major milestone in Android platform optimization with the successfu...
19/08/2026
NTP Technology announces that ST 2110-30 audio-over-IP connectivity with AES67 and RAVENNA capabilities is now available for the brand's world-class audio i...
19/08/2026
Net Insight has been selected to provide its Nimbra platform by the service provider Big Blue Marble, formerly ORS Group, as the core media transport solution f...
19/08/2026
LiveU has supported Coventry City FC and several other top-flight UK football clubs through one of their most demanding live production challenges of the year, ...
19/08/2026
Nature Seekers Documentary Shot with Blackmagic URSA Cine 12K LF
Brie Clayton August 18, 2026
0 Comments
Filming endangered turtles required camera...
19/08/2026
Neyrinck Brings D-Control Consoles Back to Life on Apple Silicon with D-Control ...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Riedel Communications today announced that Edith Cowan University (ECU) in Perth, Australia, implemented a comprehensive communications infrastructure that brin...
19/08/2026
QuickLink, a leading provider of award-winning video production and remote guest contribution solutions, will spotlight a major leap forward in remote guest con...
19/08/2026
Integrated platform melds media asset management, playout automation and newsroom workflows
EMAM, PlayBox Neo and SNEWS have officially launched Nuvex, a conne...
19/08/2026
Screen Australia releases the Private Investment Toolkit to strengthen screen in...
19/08/2026
Do Aussies truly value local content? Unpacking Screen Currency 2026 with Deirdr...
19/08/2026
There's an early Christmas gift for Bookish fans, as UKTV confirms the re-commission of the hit U&alibi drama, created by and starring Mark Gatiss. Viewers ...
19/08/2026
Wednesday 19 August 2026
Sky gives sports fans the chance to watch multiple liv...
19/08/2026
On Saturday September 5 Katie Taylor will step into the ring for the fight of her life against Flora Pili in front of 80,000 fans in Croke Park. A legendary fig...
18/08/2026
SportStream 2026, a free three-day virtual event, will take place September 15-17. One registration provides access to all three days of live programming and on...
18/08/2026
BeckTV will introduce BeckFlow to the European market at IBC2026, demonstrated on the Providius stand (10.F53).
BeckFlow is a web-based schematic documentation...
18/08/2026
Boland Communications will introduce a SMPTE ST 2110 input option for its 4K monitors at IBC2026, along with a new 55-inch super-narrow bezel display for video ...
18/08/2026
Dolby Laboratories and the Seattle Seahawks have announced a partnership integrating Dolby OptiView into the Seahawks' live streaming coverage, making the S...
18/08/2026
For BMG Executive Producer of Sports Production, Graham Taylor, producing live s...
18/08/2026
TMRW Sports has appointed Rufus Hack as President of Golf, a newly created role in which he will lead the company's golf businesses including TGL presented ...
18/08/2026
SMT will provide race technology for FOX Sports' coverage of the Freedom 250 Grand Prix of Washington, D.C. on August 23, when the NTT INDYCAR SERIES races ...
18/08/2026
The live, YouTube-native roundtables combine fan voices, credentialed reporters,...
18/08/2026
Behind The Mic provides a roundup of recent news regarding on-air talent, includ...
18/08/2026
The industry legend sounds off on replacing the Heat's iconic Medusa score...
18/08/2026
William F. Rasmussen, the sports fan-turned broadcaster and entrepreneur whose out-of-the-box idea of a 24-hour cable sports network, ESPN, changed forever the ...
18/08/2026
DAZN Group has completed its acquisition of ViewLift, a provider of streaming and digital solutions for sports content owners. The acquisition was first announc...
18/08/2026
The American Association of Professional Baseball (AAPB) has added SI TV, Sports Illustrated's 24/7 streaming channel, as a broadcast partner for the remain...
18/08/2026
The Esports Foundation has announced that the inaugural Esports Nations Cup (ENC), originally scheduled for November 2026 in Riyadh, will be postponed to Novemb...
18/08/2026
Diversified has announced a new Global Managed Services Practice, consolidating the company's managed services capabilities into one organization. Rob Mello...
18/08/2026
Appear has completed a proof of concept with Thoroughbred Racing Productions (TRP), demonstrating multi-camera remote live production over bonded 5G cellular an...
Some existing anti-cancer drugs may act in part by targeting RNA, study shows JUPITER, FL June 28, 2018 Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti-cancer drugs may work, in part, by binding tightly to RNA, the regulators of the basic activities of life within cells. The research offers another approach for tackling diseases that have been considered undruggable, including amyotrophic lateral sclerosis (ALS), muscular dystrophy, cystic fibrosis and certain cancers.
